2024
P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchReal World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
Akhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.Peer-Reviewed Original ResearchCytokine-release syndromeProgression-free survivalTreatment-related mortalityClinically significant infectionsRelapse/refractory multiple myelomaOverall survivalIde-celProlonged cytopeniasMultiple myelomaBaseline characteristicsAnti-BCMA CAR-T cell therapyHematopoietic cell transplant-specific comorbidity indexFrail patientsComorbidity indexHigh-grade adverse eventsCAR-T cell therapyRates of overall responseNon-frail patientsRate of neurotoxicityClinically important subgroupsCharlson Comorbidity IndexAge cut-offAnti-BCMAHCT-CIComplete response
2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsReal World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response rateImpact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
Ragon B, Shah M, D’Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja M, Majhail N, Banerjee R, Saad A, Hildebrandt G, Mian H, Abid M, Battiwalla M, Lekakis L, Patel S, Murthy H, Nieto Y, Strouse C, Badawy S, Al Hadidi S, Dholaria B, Aljurf M, Vesole D, Lee C, Pawarode A, Gergis U, Miller K, Holmberg L, Afrough A, Solh M, Munshi P, Nishihori T, Anderson L, Wirk B, Kaur G, Qazilbash M, Shah N, Kumar S, Usmani S. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Advances 2023, 7: 2746-2757. PMID: 36827681, PMCID: PMC10275699, DOI: 10.1182/bloodadvances.2022009138.Peer-Reviewed Original ResearchConceptsSecond hematological malignanciesSecond primary malignanciesProgression-free survivalMultiple myelomaOverall survivalMaintenance therapyDevelopment of SPMsRisk of SPMAutologous hematopoietic stem cell transplantationInferior progression-free survivalHematopoietic stem cell transplantationHigh-dose melphalanMelphalan conditioning regimenSubsequent maintenance therapyStem cell transplantationFrequent primary causeCIBMTR analysisLenalidomide maintenanceAuto-HSCTConditioning regimenMedian survivalPrimary malignancyAdult patientsCell transplantationClinical trials
2022
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
Ragon B, D'Souza A, Estrada-Merly N, Fraser R, George G, Gowda L, Shah N, Qazilbash M, Kumar S, Horowitz M, Usmani S, Shah M. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis. Journal Of Clinical Oncology 2022, 40: 8057-8057. DOI: 10.1200/jco.2022.40.16_suppl.8057.Peer-Reviewed Original ResearchSecond hematological malignanciesSecond primary malignanciesTherapy-related myeloid neoplasmsOverall survivalMultiple myelomaAllogeneic HCTMaintenance therapyDevelopment of SPMsAutologous hematopoietic stem cell transplantMarrow Transplant Research registryThree-year cumulative incidenceHematopoietic stem cell transplantHematopoietic stem cell transplantationMelphalan conditioning regimenMedian overall survivalStem cell transplantStem cell transplantationAuto-HCTCIBMTR analysisInferior PFSMedian followAllo-SCTCommonest causeConditioning regimenKarnofsky score
2018
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs
Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplantation 2018, 54: 1089-1093. PMID: 30446740, PMCID: PMC8393277, DOI: 10.1038/s41409-018-0392-1.Peer-Reviewed Original ResearchConceptsPrimary plasma cell leukemiaStem cell transplantMultiple myelomaCell transplantPost-autologous stem cell transplantAutologous stem cell transplantPoor long-term survivalPlasma cell leukemiaLong-term survivalInduction drugsCytotoxic chemotherapyAggressive variantTreatment algorithmNovel agentsCell leukemiaOutcomes postNovel drugsTransplantDrugsPosttransplantChemotherapyMyelomaTherapyLeukemia